Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.57 |
| ▸ | CASP7 | P55210 | 7/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP9 | P55211 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782015 | 0.87 | CASP3 (0.66) | CASP3CASP7CASP1CASP9PSMB5 | |
| SCHEMBL19015956 | 0.85 | CASP3 (0.57) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL20609297 | 0.78 | CASP3 (0.83) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL19015959 | 0.78 | CASP3 (0.83) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL19015958 | 0.78 | CASP3 (0.83) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL7970335 | 0.78 | CASP3 (0.83) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL19015906 | 0.78 | CASP3 (0.80) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL9961871 | 0.78 | CASP3 (0.67) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL19015889 | 0.78 | CASP3 (0.67) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL7888300 | 0.78 | CASP3 (0.67) | CASP3CASP7CASP1CASP9CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |